Health
New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19 – GlobeNewswire
Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model
CALGARY, Alberta, March 03, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) and QIMR Berghofer Medical Research Institute (QIMR Berghofer), one of Australias most successful medical research institutes, announced today the publishing of a new article providing evidence of apabetalones potential benefit on SARS-CoV-2 (COVID-19). The article, titled: Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical),…
-
General18 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Noosa News20 hours agoSurgeon partner of former premier to testify over his patient’s death
-
Business18 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General20 hours agoToo skewed, too gentlemanly | The Spectator Australia